1620 results about "Anxiety" patented technology

Disclosed are devices and methods for detecting, preventing, and/or treating neurological disorders. These devices and methods utilize electrical stimulation, and comprise a unique concentric ring electrode component. The disclosed methods involve the positioning of multiple electrodes on the scalp of a mammal; monitoring the mammal's brain electrical patterns to identify the onset of a neurological event; identifying the location of the brain electrical patterns indicative of neurological event; and applying transcutaneous or transcranial electrical stimulation to the location of the neurological event to beneficially modify brain electrical patterns. The disclosed methods may be useful in the detection, prevention, and/or treatment of a variety of indications, such as epilepsy, Parkinson's Disease, Huntington's disease, Alzheimer's disease, depression, bipolar disorder, phobia, schizophrenia, multiple personality disorder, migraine or headache, concussion, attention deficit hyperactivity disorder, eating disorder, substance abuse, and anxiety. The disclosed methods may also be used in combination with other peripheral stimulation techniques.

The invention relates to new therapeutically active and selective inhibitors of the enzyme dipeptidyl peptidase-IV, pharmaceutical compositions comprising the compounds and the use of such compounds for treating diseases that are associated with proteins that are subject to processing by DPP-IV, such as Type 2 diabetes mellitus, hyperglycemia, impaired glucose tolerance, metabolic syndrome (Syndrome X or insulin resistance syndrome), glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome and to prevent disease progression in Type 2 diabetes. The invention also relates to a method of identifying an insulin secretagogue agent for diabetes.

An efficient, objective, flexible and easily deployable system for conducting evaluations of mental and physiological state and recommending individualized treatment to improve said state is described. The method and system are based on commensurate measurement of mental functions, levels of stress and anxiety, and/or biologically active molecules such as neurotransmitters, immune markers including cytokines and hormones. The method and system are designed to assess an individual's cognitive function and the underlying physiology in order to delineate various disease processes, injuries, drug states, training stages, fatigue levels, stress levels, aging processes, predict susceptibility to stress and/or sleep deprivation, identify aptitude for training and/or characterize effects of any experimental conditions. The system and method may be used in recommending individualized treatment protocols, as well as to guide the treatment process by assessing the efficacy of such therapies in the clinical trials process.

Pharmaceutical compositions and methods for treating depression, anxiety, and neurodegenerative diseases and cognitive disorders, such as dementia and Alzheimer's disease, by administering same are provided. The compositions comprise dextromethorphan in combination with quinidine.

Disclosed herein are compositions, systems, and methods for diagnosing and treatment of subjects suffering from anxiety, autism spectrum disorder (ASD), or a pathological condition with one or more of the symptoms of ASD.

A care system and associated methods are provided for alleviating patient pain, anxiety and discomfort associated with medical or surgical procedures. The system comprises: at least one patient health monitor device coupled to a patient and generating a signal reflecting at least one physiological condition of the patient; a drug delivery controller supplying one or more drugs to the patient; a memory device storing a safety data set reflecting parameters of at least one patient physiological condition; and an electronic controller interconnected between the patient health monitor, the drug delivery controller and the safety data set. The electronic controller is capable of effecting a change in the drug supply delivered to the patient and the generation of current signals by the patient health monitor device depending on a comparison between at least one patient physiological condition at its corresponding value reflected in the safety data set.

A method for battery charge scheduling for an electric vehicle including a position confirming step for confirming a position of the vehicle, a candidate station obtaining step for obtaining information on position of the candidate battery charge station, a waiting time and a battery charge cost, a candidate battery charge station displaying step for displaying the information of the candidate battery charge stations, a candidate battery charge station selecting step for selecting a candidate battery charge station at which a battery charge is desired to be carried out and a battery charge reserving step for reserving the battery charge at the candidate battery charge station through the station control network based on a setting at the candidate battery charge station selecting step through the in-vehicle information device. By this method, user convenience is improved and actual risks and mental anxieties derived from low battery charge can be relieved or removed.

A composition comprising a mixture of fatty acids such as, linoleic, oleic and palmitic acids or deriviatives thereof dervived from secretions o mammalian mammary glands. The compositions can be utilized to decrease stress, anxiety and aggressiveness in mammals.

A compound of formula:

where Ar₁, Ar₂, X, R₃, and m are as disclosed herein or a pharmaceutically acceptable salt thereof (a “Tetrahydropiperidyl Compound”); compositions comprising an effective amount of a Tetrahydropiperidyl Compound; and methods for treating or preventing pain, UI, an ulcer, IBD, IBS, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia, or depression in an animal comprising administering to an animal in need thereof an effective amount of a Tetrahydropiperidyl Compound are disclosed herein.

The invention discloses a tumor malignant risk stratification auxiliary diagnosis system of an artificial intelligence medical image. The system comprises a data acquisition module, a data preprocessing module, a model establishment module, a model verification and optimization module, a stratification diagnosis module and a database platform. The tumor malignant risk stratification auxiliary diagnosis system of the invention is based on artificial intelligence technology, successive stratification of the malignant risk of the tumor can be achieved, the clinical diagnosis thinking is simulated, based on the high-precision ability of detecting benign lesions and malignant tumors of artificial intelligence model, and the space-occupying lesions with definite imaging features are diagnosed automatically. As a result, the system can substantially assist the clinical management decision of space-occupying lesions, improve the existing work flow of clinical diagnosis, increase the confidenceof doctors in diagnosis, reduce the work pressure, reduce the anxiety of patients with low-risk malignant lesions, greatly improve the diagnostic rate of benign lesions and malignant tumors, and hopefully realize the landing implementation of artificial intelligence clinical auxiliary diagnosis.

The invention specifies a method and system for leading a person suffering from “sympathetic predominance”, a specific symptom of which is “hypertension”, to breathe according to a certain pattern for the express purpose of positively altering the condition of sympathetic predominance (over activation), having the effect of bringing the autonomic nervous system into the state of balance, with consequent reductions in “tenseness”, blood pressure, muscular tightness, and emotional strain, as well as the alleviation of the myriad of subtle neuro-physiological consequences resulting from sympathetic predominance potentially including headaches, anxiety, sleep disorders, allergies, and other maladies that have yet to be attributed to this condition, thus leading to a general improvement in health, well being, and homeostasis. It accomplishes this by systematically reducing the breathing frequency with consequent increases in breathing depth, the ultimate goal being the realization and ongoing maintenance of 1 complete breathing cycle in 11.76 seconds or 5 complete breathing cycles in 58.8 seconds, the result being improved health, well being, and homeostasis.

Methods and compositions containing oxytocin or an oxytocin analog, specifically carbetocin, are provided for the prevention and treatment of autism spectrum disorders, related disorders and symptoms of such disorders. The methods and compositions of the invention are effective in the treatment of social withdrawal, eye contact avoidance, repetitive behaviors, anxiety, attention deficit, hyperactivity, depression, loss of speech, verbal communication difficulties, aversion to touch, visual difficulties, comprehension difficulties, and sound and light sensitivity. Additional compositions and methods are provided which employ oxytocin or an oxytocin analog in combination with a secondary or adjunctive therapeutic agent to yield more effective treatment tools against autism spectrum disorders and related disorders.

A care system and associated methods are provided for alleviating patient pain, anxiety and discomfort associated with medical or surgical procedures, the system comprising: at least one patient health monitor device coupled to a patient and generating a signal reflecting at least one physiological condition of the patient; a drug delivery controller supplying one or more drugs to the patient; a memory device storing a safety data set reflecting parameters of the at least one patient physiological condition; and an electronic controller interconnected between the patient health monitor, the drug delivery controller and the safety data set; wherein said electronic controller manages the application of the drugs in accord with the safety data set. In another aspect of the invention, the care system facilitates a procedural physician's safely and efficaciously providing conscious sedation to a patient by additionally providing a consciousness monitoring system which monitors the consciousness of the patient and generates a value representing the level of patient consciousness. Methods for alleviating patient pain and anxiety in accordance with the invention comprise connecting a drug delivery device to a patient, such device having a drug delivery controller supplying one or more drugs and being coupled to an electronic controller; attaching at least one patient health monitor device to the patient; accessing a memory device which stores a safety data set reflecting parameters of at least one patient physiological condition; and delivering the drugs to the patient in accord with the safety data set. In further aspects of the invention, the consciousness monitoring system is an automated consciousness monitoring system which includes patient query and response devices. Additional embodiments of the system and methods are directed to alleviating patient pain or discomfort while enabling safe patient controlled drug delivery in correlation with the monitoring of patient health conditions.

Piperidine Compounds; compositions comprising a Piperidine Compound; and methods for treating or preventing pain, UI, an ulcer, IBD, IBS, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia, or depression in an animal comprising administering to an animal in need thereof an effective amount of a Piperidine Compound are disclosed. In one embodiment, the Piperidine Compound has the formula:

and pharmaceutically acceptable salts thereof, wherein Ar₁, Ar₂, X, R₃, R₄, and m are as disclosed herein.

Systems, methods and devices are provided for assessing and/or treating pain, discomfort, and/or anxiety through the development of an algorithm based on a correlation between electroencephalography (EEG) signals received from a patient and the patient's self-assessed levels of pain. The pain detection algorithm is then applied to EEG signals obtained from any patient and used to assess the patient's level of pain without requiring other input from the patient. One or more devices in a system may be implemented to measure the EEG signals, apply the algorithm and display a level of pain in real-time to a patient or healthcare provider. The real-time pain assessment may be used to continuously monitor whether a patient is in pain and select one or more treatments to minimize the patient's perception of pain and avoid prescribing unnecessary medications.

The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I)

wherein all radicals are defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors-subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.

The present invention provides compositions, methods and kits for treating, preventing or reducing the risk of developing a CNS disorder. In general, the invention involves utilizing caffeine for preventing or alleviating pathological symptoms of a CNS disorder, such as headache, epilepsy, pain, Parkinson's disease, psychiatric disorders such as anxiety, bipolar disorder, depression, and schizophrenia, ADD, and ADHD.